BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $39.2 Precision Biopsy LLC $33.6 Oxford Pharmascience Group plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $39.2 Precision Biopsy LLC $33.6 Oxford Pharmascience Group plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor...
BioCentury | Dec 22, 2017
Clinical News

SciFluor reports Phase I/II data for SF0166 in wet AMD

...pressure (IOP). Secondary endpoints include mean change in anatomic center subfield thickness and macular volume. SciFluor...
...small molecule integrin antagonist to treat diabetic macular edema (DME) (see BioCentury, Oct. 6 ). SciFluor...
...center subfield thickness and macular volume Status: Phase I/II data Milestone: NA Chris Lieu SF0166 Topical Ophthalmic Solution OcuTerra Therapeutics Corp....
BioCentury | Oct 6, 2017
Clinical News

SciFluor reports Phase I/II data for DME candidate

...macular volume, best corrected visual acuity (BCVA), slit-lamp findings, fundus assessment and intraocular pressure (IOP). SciFluor...
...I/II trial of SF0166 to treat wet age-related macular degeneration (AMD) are expected this quarter. SciFluor...
BioCentury | Oct 24, 2016
Clinical News

SF0166 Topical Ophthalmic Solution: Phase I/II started

...levels of twice-daily SF0166 Topical Ophthalmic Solution for 28 days in up to 40 patients. SciFluor...
BioCentury | Jul 13, 2015
Clinical News

SciFluor preclinical data

...is a potassium channel Kv7.2 (KCNQ2) and KCNQ3 modulator and a fluorinated derivative of retigabine. SciFluor...
BioCentury | Apr 27, 2015
Financial News

SciFluor completes venture financing

SciFluor Life Sciences LLC , Cambridge, Mass. Business: Neurology, Ophthalmic, Inflammation Date completed: 2015-04-22 Type: Venture financing Raised: $30 million Investors: Invesco; Woodford Investment Management; Allied Minds WIR Staff Inflammation Neurology Ophthalmic...
BioCentury | Apr 23, 2015
Financial News

SciFluor raises $30M in series A

...Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an...
...investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated investors also participated. SciFluor...
...markets ezogabin as Potiga in the U.S. and Trobalt in the EU to treat epilepsy. SciFluor...
BioCentury | Sep 4, 2014
Strategy

Meeting of the minds

...Ontario, and Mina Bissell, professor of cell and molecular biology at Lawrence Berkeley National Laboratory SciFluor...
BioCentury | Jul 29, 2013
Clinical News

SciFluor preclinical data

...prole compared to Potiga ezogabine. Data were presented at the International Epilepsy meeting in Montreal. SciFluor...
...potassium channel opener and potentiator of GABA, as adjunctive treatment of partial-onset seizures in adults. SciFluor...
Items per page:
1 - 10 of 14
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $39.2 Precision Biopsy LLC $33.6 Oxford Pharmascience Group plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $39.2 Precision Biopsy LLC $33.6 Oxford Pharmascience Group plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor...
BioCentury | Dec 22, 2017
Clinical News

SciFluor reports Phase I/II data for SF0166 in wet AMD

...pressure (IOP). Secondary endpoints include mean change in anatomic center subfield thickness and macular volume. SciFluor...
...small molecule integrin antagonist to treat diabetic macular edema (DME) (see BioCentury, Oct. 6 ). SciFluor...
...center subfield thickness and macular volume Status: Phase I/II data Milestone: NA Chris Lieu SF0166 Topical Ophthalmic Solution OcuTerra Therapeutics Corp....
BioCentury | Oct 6, 2017
Clinical News

SciFluor reports Phase I/II data for DME candidate

...macular volume, best corrected visual acuity (BCVA), slit-lamp findings, fundus assessment and intraocular pressure (IOP). SciFluor...
...I/II trial of SF0166 to treat wet age-related macular degeneration (AMD) are expected this quarter. SciFluor...
BioCentury | Oct 24, 2016
Clinical News

SF0166 Topical Ophthalmic Solution: Phase I/II started

...levels of twice-daily SF0166 Topical Ophthalmic Solution for 28 days in up to 40 patients. SciFluor...
BioCentury | Jul 13, 2015
Clinical News

SciFluor preclinical data

...is a potassium channel Kv7.2 (KCNQ2) and KCNQ3 modulator and a fluorinated derivative of retigabine. SciFluor...
BioCentury | Apr 27, 2015
Financial News

SciFluor completes venture financing

SciFluor Life Sciences LLC , Cambridge, Mass. Business: Neurology, Ophthalmic, Inflammation Date completed: 2015-04-22 Type: Venture financing Raised: $30 million Investors: Invesco; Woodford Investment Management; Allied Minds WIR Staff Inflammation Neurology Ophthalmic...
BioCentury | Apr 23, 2015
Financial News

SciFluor raises $30M in series A

...Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an...
...investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated investors also participated. SciFluor...
...markets ezogabin as Potiga in the U.S. and Trobalt in the EU to treat epilepsy. SciFluor...
BioCentury | Sep 4, 2014
Strategy

Meeting of the minds

...Ontario, and Mina Bissell, professor of cell and molecular biology at Lawrence Berkeley National Laboratory SciFluor...
BioCentury | Jul 29, 2013
Clinical News

SciFluor preclinical data

...prole compared to Potiga ezogabine. Data were presented at the International Epilepsy meeting in Montreal. SciFluor...
...potassium channel opener and potentiator of GABA, as adjunctive treatment of partial-onset seizures in adults. SciFluor...
Items per page:
1 - 10 of 14